ES2526211T3 - Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos - Google Patents

Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos Download PDF

Info

Publication number
ES2526211T3
ES2526211T3 ES08781680.7T ES08781680T ES2526211T3 ES 2526211 T3 ES2526211 T3 ES 2526211T3 ES 08781680 T ES08781680 T ES 08781680T ES 2526211 T3 ES2526211 T3 ES 2526211T3
Authority
ES
Spain
Prior art keywords
cells
antibodies
weak
activation
signal transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08781680.7T
Other languages
English (en)
Spanish (es)
Inventor
Sharat Singh
Jeanne Harvey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Application granted granted Critical
Publication of ES2526211T3 publication Critical patent/ES2526211T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES08781680.7T 2007-07-13 2008-07-11 Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos Active ES2526211T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94982007P 2007-07-13 2007-07-13
US949820P 2007-07-13
PCT/US2008/069764 WO2009012140A2 (en) 2007-07-13 2008-07-11 Drug selection for lung cancer therapy using antibody-based arrays

Publications (1)

Publication Number Publication Date
ES2526211T3 true ES2526211T3 (es) 2015-01-08

Family

ID=40260313

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08781680.7T Active ES2526211T3 (es) 2007-07-13 2008-07-11 Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos

Country Status (15)

Country Link
US (1) US9250243B2 (https=)
EP (1) EP2179291B1 (https=)
JP (1) JP5352585B2 (https=)
KR (1) KR101553723B1 (https=)
CN (1) CN101802618B (https=)
AU (1) AU2008276251B2 (https=)
BR (1) BRPI0813583A2 (https=)
CA (1) CA2693013A1 (https=)
ES (1) ES2526211T3 (https=)
IL (1) IL203201A (https=)
MX (1) MX2010000405A (https=)
NZ (1) NZ582618A (https=)
RU (2) RU2519647C2 (https=)
WO (1) WO2009012140A2 (https=)
ZA (1) ZA201000310B (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
ES2526211T3 (es) 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
WO2009094556A2 (en) * 2008-01-25 2009-07-30 Bristol-Myers Squibb Pharma Company Identification of predictive markers of response to dasatinib in human colon cancer
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
EP2239579A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for the predicting of the response of non-small cell lung cancer patients to targeted pharmacotherapy
JP5718319B2 (ja) * 2009-05-14 2015-05-13 ネステク ソシエテ アノニム Ｈｅｒ２標的化療法に対する乳癌細胞の感受性を決定するためのバイオマーカー
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
MX337666B (es) 2009-10-20 2016-03-14 Nestec Sa Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.
EP2540738A4 (en) 2009-12-28 2013-01-02 Kikkoman Corp PROCESS FOR EXTRACTION OF STAPHYLOCOCCUS AUREUS NATIGEN, REAGENT FOR EXTRACTION OF STAPHYLOCOCCUS AUREUS ANTIGEN AND METHOD FOR TESTING STAPHYLOCOCCUS AUREUS
US8883985B2 (en) 2010-02-16 2014-11-11 National University Corporation Kyoto Institute Of Technology Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier
US8574922B2 (en) * 2010-03-08 2013-11-05 Bin Hong Targeted cell separation and enumeration device and the use thereof
US20110318336A1 (en) * 2010-03-29 2011-12-29 George Mason Intellectual Properties, Inc. Identification and Treatment of Aggressive Lung Cancer Tumors
US20110301859A1 (en) * 2010-06-04 2011-12-08 N-Of-One Therapeutics, Inc. Personalized molecular medicine
WO2011158863A1 (ja) * 2010-06-16 2011-12-22 国立大学法人九州大学 タンパク質キナーゼの新規基質ペプチド
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
RU2565550C2 (ru) 2010-09-24 2015-10-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Прямой захват, амплификация и секвенирование днк-мишени с использованием иммобилизированных праймеров
EP2656077A1 (en) * 2010-12-23 2013-10-30 Nestec S.A. Drug selection for malignant cancer therapy using antibody-based arrays
WO2012086802A1 (ja) 2010-12-24 2012-06-28 アークレイ株式会社 癌細胞の検出方法
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
SG192270A1 (en) 2011-02-17 2013-08-30 Nestec Sa Apparatus and method for isolating leukocytes and tumor cells by filtration
DK2676137T3 (en) 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
WO2012119113A2 (en) 2011-03-02 2012-09-07 Nestec Sa Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
EP2694972B8 (en) 2011-04-04 2017-08-16 Pierian Holdings, Inc. Methods for predicting and improving the survival of gastric cancer patients
US20140010886A1 (en) * 2011-04-07 2014-01-09 Georgia Tech Research Corporation Compositions comprising saccharide binding moieties and methods for targeted therapy
JP2014517279A (ja) 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
MX343324B (es) 2011-07-06 2016-11-01 Nestec Sa Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
JP6186575B2 (ja) 2011-09-02 2017-08-30 ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング
CN102998439A (zh) * 2011-09-14 2013-03-27 佳木斯大学 同时检测葡萄糖、尿酸、甘油三酯及胆固醇的微流控纸芯片及制造方法
EP2788752B1 (en) * 2011-12-05 2018-10-03 Pierian Holdings, Inc. Method of therapy selection for patients with lung cancer
EP2605014A1 (en) * 2011-12-16 2013-06-19 Merck Patent GmbH General strategy for antibody library screening
EP2831587B1 (en) 2012-03-27 2018-05-16 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
EP3605090A1 (en) * 2012-05-23 2020-02-05 F. Hoffmann-La Roche AG Selection method for therapeutic agents
CN102841201B (zh) * 2012-08-31 2015-06-03 马鞍山微因泰克生物科技有限公司 一种以肺癌为主的早期癌症联合普查蛋白芯片
JP2015532425A (ja) 2012-10-05 2015-11-09 ネステク ソシエテ アノニム 粘膜治癒を予測及びモニタリングするための方法
US20150259430A1 (en) * 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
EP2954328A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
EP2954068B8 (en) 2013-02-05 2018-10-31 Pierian Holdings, Inc. Drug selection for non-small cell lung cancer therapy
EP2972227B1 (en) 2013-03-12 2020-05-06 Ventana Medical Systems, Inc. Digitally enhanced microscopy for multiplexed histology
WO2014188363A1 (en) 2013-05-21 2014-11-27 Nestec S.A. Methods for predicting and improving the survival of colorectal cancer patients
JP6799201B2 (ja) * 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
RU2571821C2 (ru) * 2013-09-26 2015-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Способ выявления циркулирующих опухолевых клеток, микроэмбол и апоптотических телец в крови больных раком легкого человека
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR101527797B1 (ko) * 2014-06-03 2015-06-15 한국과학기술원 신호전달경로의 활성화 상태 분석방법 및 이를 이용한 개인 맞춤형 치료제의 선정방법
MX2017004742A (es) 2014-10-20 2017-07-20 Nestec Sa Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
WO2016088104A2 (en) 2014-12-05 2016-06-09 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
WO2016112272A1 (en) * 2015-01-09 2016-07-14 Metastat, Inc. Method of use for inhibitors of epidermal growth factor receptor variant iii
CN106854246B (zh) * 2015-12-09 2020-05-22 南京英瀚斯生物科技有限公司 一种针对pi3k的纳米抗体及其临床应用
RU2616533C1 (ru) * 2016-03-15 2017-04-17 Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) Способ прогнозирования эффективности терапии эверолимусом у больных метастатическим раком почки
CN106093394B (zh) * 2016-06-07 2017-12-26 中国人民解放军第二军医大学 Flt3蛋白在制备肝癌对索拉菲尼疗效评估试剂盒中的应用
US10761081B2 (en) * 2016-06-12 2020-09-01 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
AU2018277256A1 (en) 2017-05-31 2020-01-30 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in Crohn's disease patients
CA3066507A1 (fr) * 2017-06-08 2018-12-13 Carcidiag Biotechnologies Methode d'isolement et de detection de cellules souches cancereuses
KR101897250B1 (ko) * 2017-07-11 2018-09-10 광주과학기술원 항암제 조합에 대한 단일 세포 분석 칩
EP3665307B1 (en) 2017-08-10 2022-09-28 The Institute of Cancer Research: Royal Cancer Hospital Materials and methods for stratifying and treating cancers
US10871485B2 (en) 2018-04-13 2020-12-22 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
CN110031626A (zh) * 2019-04-02 2019-07-19 浙江理工大学 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用
EP3968963A4 (en) 2019-05-16 2023-02-01 Aerovate Therapeutics, Inc. IMATINIB FORMULATIONS, THEIR PREPARATION AND USES
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
WO2022155311A1 (en) * 2021-01-14 2022-07-21 The Regents Of The University Of California Methods and systems for analysis of drug target engagement and treatment of cancer
WO2023283537A2 (en) * 2021-07-07 2023-01-12 Institute For Systems Biology Cell analysis methods, compositions, and uses
WO2023058624A1 (ja) * 2021-10-08 2023-04-13 コニカミノルタ株式会社 染色方法、評価方法および標本

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4975532A (en) 1986-11-28 1990-12-04 Sclavo, Inc. Method to derivatize dextran
JPH01163661A (ja) 1987-10-02 1989-06-27 E I Du Pont De Nemours & Co ＩｇＧ捕捉抗体および多重単クローン性抗体検出系を用いたイムノアツセイ
US5089419A (en) 1989-08-07 1992-02-18 International Canine Genetics Detection of pregnancy by identification of the c peptide of relaxin in the urine of animals
US5120660A (en) 1989-12-05 1992-06-09 International Canine Genetics, Inc. Method for canine fertility detection
FR2672128B1 (fr) 1991-01-28 1995-08-18 Cis Bio Int Procede de mesure de la luminescence emise dans un dosage par luminescence.
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
JPH06109734A (ja) 1992-09-30 1994-04-22 S R L:Kk 抗原の測定方法
US6201109B1 (en) 1993-01-13 2001-03-13 Dade Behring Marburg Gmbh Assay for bone alkaline phosphatase
JP3825815B2 (ja) 1994-01-31 2006-09-27 信義 清水 上皮細胞増殖因子レセプターに対するモノクローナル抗体の結合体ならびにその複合体およびその細胞への嵌入方法
FI98961C (fi) 1994-08-26 1997-09-10 Medix Biochemica Ab Oy Menetelmät ja määritysvälineet parodontaalisairauden aktiivisuuden ja/tai peri-implantiitin ja/tai niiden kohonneen riskin diagnosoimiseksi
US5876944A (en) 1996-06-10 1999-03-02 Bayer Corporation Method for amplification of the response signal in a sandwich immunoassay
US6780596B2 (en) * 1998-09-17 2004-08-24 Ashni Naturaceuticals, Inc. Methods for determining the activity of complex mixtures
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
RU2165081C2 (ru) * 1999-01-05 2001-04-10 Ставропольский научно-исследовательский противочумный институт Способ индикации микроорганизмов
US6335173B1 (en) * 1999-01-12 2002-01-01 Verve, Ltd. C/O James Bell Methods for detecting an analyte of interest using tyramide coating technology
GB9901072D0 (en) 1999-01-19 1999-03-10 Imp Cancer Res Tech Methods for detecting changes to a macromolecular component of a cell
US6972198B2 (en) 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using protein binding partners
RU2149404C1 (ru) 1999-03-24 2000-05-20 Московский НИИ глазных болезней им. Гельмгольца Способ прогнозирования клинического течения увеальной меланомы
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6649351B2 (en) 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
DE19926010C2 (de) 1999-06-08 2003-01-30 Bundesdruckerei Gmbh Wert- und Sicherheitsdokument mit Sicherheitsmerkmal mit Piezo-Effekt-basierten Eigenschaften und dazugehöriges Nachweisverfahren
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
WO2001027624A2 (en) 1999-10-08 2001-04-19 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
AU760486B2 (en) 1999-10-13 2003-05-15 Incyte Genomics, Inc. Multiplex cytokine analysis
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US6511809B2 (en) 2000-06-13 2003-01-28 E. I. Du Pont De Nemours And Company Method for the detection of an analyte by means of a nucleic acid reporter
CA2422162C (en) 2000-09-09 2012-10-23 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
US6797481B1 (en) 2000-10-17 2004-09-28 Dade Behring Marburg Gmbh Simultaneous screening of multiple analytes
US7635571B2 (en) 2000-12-07 2009-12-22 Siemens Healthcare Diagnostics Products Gmbh Amplified signal in binding assays
DE10064827A1 (de) 2000-12-22 2002-06-27 Dade Behring Marburg Gmbh Nachweisverfahren
US20070111944A1 (en) 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20020168641A1 (en) 2001-03-09 2002-11-14 Bruce Mortensen Fluorescein-cyanine 5 as a fluorescence resonance energy transfer pair
US20020142361A1 (en) 2001-03-27 2002-10-03 Emmert-Buck Michael R. Biodetection method
US20040265923A1 (en) * 2001-05-03 2004-12-30 James Gilmore Method and apparatus to determine the performance of protein arrays
EP1409982A4 (en) 2001-06-14 2006-05-24 Anadys Pharmaceuticals Inc PROCESS FOR SCREENING ON LIGANDS OF TARGET MOLECULES
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
WO2003006104A2 (en) 2001-07-12 2003-01-23 Ludwig Institute For Cancer Research Lymphatic endothelial cells materials and methods
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US8323903B2 (en) 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
WO2003040670A2 (en) 2001-11-07 2003-05-15 Sensor Technologies Llc Method of identifying energy transfer sensors for analytes
US6949347B2 (en) 2002-03-05 2005-09-27 Aclara Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
AU2003223495A1 (en) 2002-04-05 2003-10-27 Cell Signaling Technology, Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
FR2843126B1 (fr) 2002-08-01 2006-01-27 Cis Bio Int "methode de determination d'une activite enzymatique endoglycosidase"
US20040235002A1 (en) 2002-09-20 2004-11-25 Sangamo Biosciences, Inc. Multiplex screening assays
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
CA2504042A1 (en) * 2002-11-05 2004-05-27 The Regents Of The University Of California Methods and materials for examining pathways associated with glioblastoma progression
US20030153013A1 (en) 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
CA2515096A1 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
JP3857677B2 (ja) * 2003-02-18 2006-12-13 和久 蓮井 免疫組織化学的染色による抗原の検出方法
CA2521077A1 (en) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Erbb surface receptor complexes as biomarkers
WO2004099407A1 (ja) * 2003-05-09 2004-11-18 Chemical Biology Institute 抗癌剤感受性試験方法
JP2006340602A (ja) * 2003-06-13 2006-12-21 Orient Cancer Therary:Kk モデルマウス
US20040265938A1 (en) 2003-06-25 2004-12-30 Jose Remacle Method for the determination of cell activation
US20060281093A1 (en) * 2003-08-05 2006-12-14 Richard Kim Erbb receptor methods and kits for monitoring chemotherapy resistance
US7279286B2 (en) 2003-09-11 2007-10-09 Sanofi-Aventis Deutschland Gmbh High-throughput-assay with high sensitivity for measuring of the activity of β-adrenergic receptor kinase and for determining the impact of test substances on such activity
FI20031370A0 (fi) 2003-09-23 2003-09-23 Wallac Oy Automaattinen hemoglobiinin määritysmenetelmä vastasyntyneiden seulontaan
EP1681983A4 (en) 2003-10-14 2008-12-10 Monogram Biosciences Inc RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY
EP1682512B1 (en) 2003-11-04 2010-03-31 Bayer Pharmaceuticals Corporation IMMUNOHISTOCHEMICAL METHODS FOR MONITORING pERK LEVELS
JP2007526460A (ja) 2004-03-03 2007-09-13 バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞集団のタンパク質発現プロファイルの作成のための分析用プラットフォームおよび方法
DK2299275T3 (en) 2004-07-30 2018-05-07 Adeza Biomedical Corp Classification of oncofetal fetronectin level for pregnancy-related indications
WO2006031815A2 (en) * 2004-09-13 2006-03-23 Monogram Biosciences, Inc. Methods and compositions for proximity assays
US20080254497A1 (en) 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
WO2006045991A1 (en) 2004-10-25 2006-05-04 Astrazeneca Ab Method to predict whether a tumor will react to a chemotherapeutic treatment
US20090068162A1 (en) * 2004-11-17 2009-03-12 Robert Sack Stationary Phase Antibody Arrays for Trace Protein Analysis
WO2006054991A1 (en) 2004-11-17 2006-05-26 Immunivest Corporation Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection
DE102004056794B4 (de) 2004-11-24 2010-08-26 Protagen Ag Verwendung einer Anordnung und Verfahren zur Validierung von Bindern
WO2006082866A1 (ja) * 2005-02-01 2006-08-10 Banyu Pharmaceutical Co., Ltd. ｐ５３の機能異常の検出方法、癌の分子診断方法及び癌治療に有効な化合物の評価方法
CA2601157A1 (en) * 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
WO2007130677A2 (en) 2006-05-05 2007-11-15 Yale University Use of subcellular localization profiles as prognostic or predictive indicators
CA2663595A1 (en) 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Proteomic patterns of cancer prognostic and predictive signatures
DK2064549T3 (da) * 2006-09-21 2013-02-04 Nestec Sa Antistof-baserede arrays til detektion af flere signaltransducere i sjældne cirkulerende celler
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
BRPI0718413A2 (pt) 2006-10-23 2014-03-11 The Uab Research Foundation Métodos para prever a sensibilidade de uma célula concerosa a um primeiro agente anticâncer, para prever ou monitorar a eficácia de um agente anticâncer, e para determinar uma dose eficaz para um agente anticâncer, kit de detecção, e, sistema de ensaio multiplex
DK2080012T3 (da) 2006-11-10 2013-06-17 Dimerix Bioscience Pty Ltd Fremgangsmåder til analyse af testforbindelser på forbundne receptorer.
JP5656406B2 (ja) 2006-11-28 2015-01-21 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツングＵ３ Ｐｈａｒｍａ ＧｍｂＨ 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
JP2008292424A (ja) 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
ES2526211T3 (es) 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
EP2065475A1 (en) 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
US20120270745A1 (en) 2009-07-15 2012-10-25 Prometheus Laboratories Inc. Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
US20120231965A1 (en) 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling

Also Published As

Publication number Publication date
MX2010000405A (es) 2010-03-04
RU2519647C2 (ru) 2014-06-20
NZ582618A (en) 2012-07-27
ZA201000310B (en) 2011-04-28
RU2010105037A (ru) 2011-08-20
CN101802618A (zh) 2010-08-11
KR20100063011A (ko) 2010-06-10
CN101802618B (zh) 2015-02-25
JP2010533842A (ja) 2010-10-28
JP5352585B2 (ja) 2013-11-27
CA2693013A1 (en) 2009-01-22
AU2008276251A1 (en) 2009-01-22
AU2008276251B2 (en) 2014-04-24
KR101553723B1 (ko) 2015-09-16
US9250243B2 (en) 2016-02-02
WO2009012140A2 (en) 2009-01-22
EP2179291A2 (en) 2010-04-28
EP2179291B1 (en) 2014-10-22
BRPI0813583A2 (pt) 2014-12-30
WO2009012140A3 (en) 2009-03-05
US20110275097A9 (en) 2011-11-10
RU2013142450A (ru) 2015-03-27
IL203201A (en) 2015-08-31
US20090035792A1 (en) 2009-02-05
EP2179291A4 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
ES2526211T3 (es) Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
ES2398618T3 (es) Selección de fármacos para terapia del cáncer de mama utilizando matrices de anticuerpos
ES2637853T3 (es) Ensayos mediados por proximidad para detectar proteínas de fusión oncogénicas
CA2768013C (en) Drug selection for gastric cancer therapy using antibody-based arrays
EP2751562B1 (en) Profiling of signal pathway proteins to determine therapeutic efficacy
CA2822283A1 (en) Drug selection for malignant cancer therapy using antibody-based arrays
US20120270745A1 (en) Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples
HK1175529B (en) Proximity-mediated assays for detecting oncogenic fusion proteins